Sofpironium bromide

The importance of Sofpironium bromide is indisputable in today's society. For decades, Sofpironium bromide has been a recurring topic in debates, research and discussions in different areas. Its influence ranges from personal, social, political, economic and cultural aspects, impacting the way people approach their daily lives. Sofpironium bromide has been the subject of attention of academics, scientists, opinion leaders and professionals, seeking to understand its scope and consequences. In this article, we will explore in detail the relevance of Sofpironium bromide and its impact on modern society.

Sofpironium bromide
Clinical data
Trade namesEcclock, others
Other namesBBI-4000, BBI 4000
AHFS/Drugs.comMonograph
License data
Routes of
administration		Topical
Drug classAnticholinergic
ATC code
  • None
Legal status
Legal status
Identifiers
  • (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate bromide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H32BrNO5
Molar mass470.404 g·mol−1
3D model (JSmol)
  • CCOC(=O)C1(CC(C1)OC(=O)(C2CCCC2)(C3=CC=CC=C3)O)C.
  • InChI=1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1
  • Key:FIAFMTCUJCWADZ-JOFREBOKSA-M

Sofpironium bromide, sold under the brand name Ecclock among others, is a medication used to treat hyperhidrosis (excessive sweating).[1] Sofpironium bromide is an anticholinergic agent that is applied to the skin.[1]

It was approved for medical use in Japan in 2020,[2] and in the United States in June 2024.[1][3][4][5]

Medical uses

Sofpironium bromide is indicated for the treatment of primary axillary hyperhidrosis.[1]

Mechanism of action

The pharmacodynamics of sofpironium bromide are unknown.[1]

Society and culture

It was approved for medical use in Japan in November 2020,[6] and in the United States in June 2024.[1][7]

Brand names

Sofpironium bromide is the international nonproprietary name.[8]

It is sold under the brand name Ecclock in Japan and under the brand name Sofdra in the US.

References

  1. ^ a b c d e f g "Sofdra- sofpironium bromide gel". DailyMed. 26 August 2024. Retrieved 2 September 2024.
  2. ^ Paik J (December 2020). "Sofpironium Bromide: First Approval". Drugs. 80 (18): 1981–1986. doi:10.1007/s40265-020-01438-1. PMID 33236266. S2CID 227155835.
  3. ^ "Drug Approval Package: Sofdra". U.S. Food and Drug Administration (FDA). 17 July 2024. Retrieved 2 September 2024.
  4. ^ New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
  5. ^ "FDA Approves Sofdra topical gel" (Press release). Botanix Pharmaceuticals. 20 June 2024. Archived from the original on 20 June 2024. Retrieved 20 June 2024.
  6. ^ "Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (Ecclock) in Japan by its Development Partner, Kaken Pharmaceutical" (Press release). Brickell Biotech. 18 November 2020. Retrieved 2 September 2024 – via GlobeNewswire.
  7. ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
  8. ^ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1). hdl:10665/330984.

Further reading